טוען...

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

INTRODUCTION: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD. Since the cost-effectiveness of dupilumab has not been evaluate...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Dermatol Ther (Heidelb)
Main Authors: Kuznik, Andreas, Bégo-Le-Bagousse, Gaëlle, Eckert, Laurent, Gadkari, Abhijit, Simpson, Eric, Graham, Christopher N., Miles, LaStella, Mastey, Vera, Mahajan, Puneet, Sullivan, Sean D.
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer Healthcare 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698200/
https://ncbi.nlm.nih.gov/pubmed/28933010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-017-0201-6
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!